To: FJB who wrote (1254378 ) 8/15/2020 8:17:28 AM From: Winfastorlose 2 RecommendationsRecommended By FJB locogringo
Respond to of 1576349 Yale Prof: Hydroxychloroquine Haters Spewing 'Misleading And Toxic Disinformation' Fri, 08/14/2020 - 12:30 Yale epidemiology professor Harvey Risch has hit back against critics and says he's been the subject of personal attacks over his insistence that hydroxychloroquine is highly effective in treating COVID-19 if administered early in the disease's progression. In a Washington Examiner Op-Ed, Risch writes that the pushback against his advocacy for the drug has been "furious."Dr. Anthony Fauci has implied that I am incompetent , notwithstanding my hundreds of highly regarded, methodologically relevant publications in peer-reviewed scientific literature. A group of my Yale colleagues has publicly intimated that I am a zealot who is perpetrating a dangerous hoax and conspiracy theory . I have been attacked in news articles by journalists who, ignorant of the full picture, have spun hit pieces from cherry-picked sources. -Harvey Risch Risch says the personal attacks are a "dangerous distraction from the real issue of hydroxychloroquine's effectiveness, which is solidly grounded in both substantial evidence and appropriate medical decision-making logic." He adds that there a no studies - published or in pre-print - which disprove his theory that HCQ should be used on high-risk outpatients, and that "assertions to the contrary, whether by Faucci, the FDA, or anyone else, are without foundation. They constitute misleading and toxic disinformation. "Covid-19 has 'two main stages' according to Risch, and HCQ works well in the first, but not the second, later stage of the disease:At the first stage, it is a flu-like illness. That illness will not kill you. If you are a high-risk patient and begin treatment immediately, you will almost certainly be done with it in a few days . When not treated, high-risk patients may progress. The virus then causes severe pneumonia and attacks many organs, including the heart. In this second stage, hydroxychloroquine is not effective . So, as Risch points out, it's important to distinguish which patients HCQ works best for ; "Does it not work in those who have just started to have symptoms, or those sick enough to require hospitalization?" Secondly, Risch notes that most low-risk patients, those below 60 with no underlying comorbidities, typically survive without treatment . High risk patients are those over the age of 60, or those with chronic conditions such as obesity, diabetes, hypertension, and immunocompromised individuals. "High-risk patients need immediate treatment when they first show symptoms, " Risch writes. "One should not wait for the COVID-19 test result, which can take days and be wrong."Every randomized controlled trial to date that has looked at early outpatient treatment has involved low-risk patients, patients who are not generally treated . In these studies, so few untreated control patients have required hospitalization that significant differences were not found. There has been only one exception: In a study done in Spain with low-risk patients, a small number of high-risk nursing home patients were included. For those patients, the medications cut the risk of a bad outcome in half. I reiterate: If doctors, including any of my Yale colleagues, tell you that scientific data show that hydroxychloroquine does not work in outpatients, they are revealing that they can’t tell the difference between low-risk patients who are not generally treated and high-risk patients who need to be treated as quickly as possible . Doctors who do not understand this difference should not be treating COVID-19 patients. -Harvey Risch Read the rest of Risch's Op-Ed here .